Association of Interleukin-8 (Il-8) Level on Benign and Malignant Type of Ovarian Neoplasm
Main Article Content
Abstract
Objective: Ovarian cancer is a global problem and is the eighth most common type of cancer in women. The proinflammatory IL-8 cytokine has been established as an immunoregulatory cytokine. Ovarian cancer cells continuously secrete this cytokine which increases its tumorigenicity
Methods: Observational study with cross-sectional design. The sample of this study were ovarian neoplasm patients who underwent surgery at Dr. Wahidin Sudirohusodo hospital and the networking hospitals. The sampling was done by consecutive random sampling. Measurement of serum IL-8 was conducted using the ELISA method. Data were analyzed by chi-square test.
Result: Serum IL-8 levels were found to be associated with staging and histopathological results in ovarian neoplasms with a significant elevation of IL-8 levels at a mean value of 146.10 pg/mL (p <0.05) in advanced stage ovarian neoplasm and at a mean value of 152.43 pg/mL (p <0.05) in ovarian neoplasm with epithelial histopathology results. Although an increase in serum IL-8 levels was also observed in the ovarian neoplasm group with an abnormal CA-125 result with a mean value of 124.16 pg/mL (p > 0.05), malignant RMI with a mean value of 148.91 pg/mL (p > 0.05), and cytology containing malignant cells with a mean value of 167.68 pg/mL (p > 0.05), these findings were not statistically significant.
Conclusion: In this study, it was concluded that IL-8 levels were significantly increased in ovarian neoplasms with advanced stage and histopathological results of epithelial type.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016: Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians. 2016;66(1):7-30. doi:10.3322/caac.21332
II. Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, et al. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treatment Reviews. 2017;60:24-31. doi:10.1016/j.ctrv.2017.08.004
III. Wang Y, Xu RC, Zhang XL, et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 2012;59(1):145-155. doi:10.1016/j.cyto.2012.04.013
IV. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. IJWH. 2019;Volume 11:287-299. doi:10.2147/IJWH.S197604
V. Tortorella L, Vizzielli G, Fusco D, et al. Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments. Aging and disease. 2017;8(5):677. doi:10.14336/AD.2017.0607
VI. Olsen CM, Nagle CM, Whiteman DC, et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer. 2013;20(2):251-262. doi:10.1530/ERC-12-0395
VII. Khieri SA, Kunna A, Babiker AY, Alsuhaibani SA, Ahmed RY, Alsammani MA. Histopathological Pattern and Age Distribution, of Malignant Ovarian Tumor among Sudanese Ladies. Open Access Maced J Med Sci. 2018;6(2):237-241. doi:10.3889/oamjms.2018.067
VIII. Akakpo PK, Derkyi-Kwarteng L, Gyasi RK, Quayson SE, Anim JT. Ovarian Cancer in Ghana, a 10 Year Histopathological Review of Cases at Korle Bu Teaching Hospital. Ovarian Cancer.
IX. Australian Ovarian Cancer Study Group, for the Ovarian Cancer Association Consortium, Nagle CM, et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer. 2015;113(5):817-826. doi:10.1038/bjc.2015.245
X. Modugno F, Edwards RP. Ovarian Cancer: Prevention, Detection, and Treatment of the Disease and its Recurrence. Molecular Mechanisms and Personalized Medicine Meeting Report. Int J Gynecol Cancer. 2012;22(Supp 2):S45-S57. doi:10.1097/IGC.0b013e31826bd1f2
XI. Sieh W, Köbel M, Longacre TA, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. The Lancet Oncology. 2013;14(9):853-862. doi:10.1016/S1470-2045(13)70253-5
XII. Huang. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. int J Oncol. Published online January 1, 1992. doi:10.3892/ijo_00000083
XIII. Wang X, Li X, Su S, Liu M. Marital status and survival in epithelial ovarian cancer patients: a SEER-based study. Oncotarget. 2017;8(51):89040-89054. doi:10.18632/oncotarget.21648
XIV. Girolimetti G, Perrone AM, Santini D, et al. BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management. BioMed Research International. 2014;2014:1-11. doi:10.1155/2014/787143
XV. Rusda M, Rivany R, Hasibuan CL, Lutan D, Aldiansyah D, Adella CA. IHC Expression Relationships MMP7 and VEGF With Normal Ovaries and Ovarian Pathologies. SMJ. 2019;2(1):47-54. doi:10.32734/sumej.v2i1.719
XVI. Yazdani S, Javadian M, Bouzari Z, Ranaei M, Hajian K, Ghafari A. The Predictive Role of Preoperative Leukocytosis, Anemia and Thrombocytosis with the Severity of Epithelial Ovarian Tumors. Published online 2018.
XVII. Bakacak M, Serin S, Ercan O, et al. Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses. J Turkish German Gynecol Assoc. 2016;17(1):21-25. doi:10.5152/jtgga.2015.0152
XVIII. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015: Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians. 2016;66(2):115-132. doi:10.3322/caac.21338
XIX. Feng Y, Wang Z, Cui R, et al. Clinical analysis and artificial intelligence survival prediction of serous ovarian cancer based on preoperative circulating leukocytes. J Ovarian Res. 2022;15(1):64. doi:10.1186/s13048-022-00994-2
XX. Yildirim M, Demir Cendek B, Filiz Avsar A. Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. Molecular and Clinical Oncology. 2015;3(2):317-321. doi:10.3892/mco.2014.481
XXI. Hufnagel DH, Cozzi GD, Crispens MA, Beeghly-Fadiel A. Platelets, Thrombocytosis, and Ovarian Cancer Prognosis: Surveying the Landscape of the Literature. IJMS. 2020;21(21):8169. doi:10.3390/ijms21218169
XXII. Boivin M, Lane D, Piché A, Rancourt C. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecologic Oncology. 2009;115(3):407-413. doi:10.1016/j.ygyno.2009.08.007
XXIII. Bristow R, Jordan. Ovarian cancer biomarkers as diagnostic triage tests. CBF. Published online February 2013:35. doi:10.2147/CBF.S30228
XXIV. Cambruzzi E, Lima R de, Teixeira SL, Pêgas KL. The relationship between serum levels of CA 125 and the degree of differentiation in ovarian neoplasms. J Bras Patol Med Lab. 2014;50(1):20-25. doi:10.1590/S1676-24442014000100003
XXV. Pawlik W, Pawlik J, Kozłowski M, et al. The Clinical Importance of IL-6, IL-8, and TNF-α in Patients with Ovarian Carcinoma and Benign Cystic Lesions. Diagnostics. 2021;11(9):1625. doi:10.3390/diagnostics11091625
XXVI. Moolthiya W, Yuenyao P. The Risk of Malignancy Index (RMI) in Diagnosis of Ovarian Malignancy.
XXVII. Javdekar R, Maitra N. Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass. J Obstet Gynecol India. 2015;65(2):117-121. doi:10.1007/s13224-014-0609-1
XXVIII. Zhang L, Liu W, Wang X, Wang X, Sun H. Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy. Oncol Lett. Published online December 18, 2018. doi:10.3892/ol.2018.9842